Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) Net Income towards Common Stockholders (2018 - 2025)

Historic Net Income towards Common Stockholders for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$708991.0.

  • BioNexus Gene Lab's Net Income towards Common Stockholders rose 4730.14% to -$708991.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 15562.48%. This contributed to the annual value of -$1.6 million for FY2024, which is 3920.44% up from last year.
  • BioNexus Gene Lab's Net Income towards Common Stockholders amounted to -$708991.0 in Q3 2025, which was up 4730.14% from -$616172.0 recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's Net Income towards Common Stockholders peaked at $671809.0 during Q4 2021, and registered a low of -$2.6 million during Q3 2023.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$77401.0 (2022), whereas its average is -$265791.2.
  • Data for BioNexus Gene Lab's Net Income towards Common Stockholders shows a peak YoY increase of 77148.37% (in 2023) and a maximum YoY decrease of 327100.17% (in 2023) over the last 5 years.
  • Over the past 5 years, BioNexus Gene Lab's Net Income towards Common Stockholders (Quarter) stood at $671809.0 in 2021, then tumbled by 107.79% to -$52349.0 in 2022, then surged by 771.48% to $351515.0 in 2023, then tumbled by 199.09% to -$348319.0 in 2024, then plummeted by 103.55% to -$708991.0 in 2025.
  • Its Net Income towards Common Stockholders was -$708991.0 in Q3 2025, compared to -$616172.0 in Q2 2025 and -$623327.0 in Q1 2025.